Sporadic Burkitt lymphomas of children and adolescents in Chinese: a clinicopathological study of 43 cases by Cheng-Feng Bi et al.
RESEARCH Open Access
Sporadic Burkitt lymphomas of children and
adolescents in Chinese: a clinicopathological
study of 43 cases
Cheng-Feng Bi, Yuan Tang, Wen-Yan Zhang, Sha Zhao, Xiao-Qing Wang, Qun-Pei Yang, Gan-Di Li and Wei-ping Liu*
Abstract
Background: To investigate the clinical and pathologic features as well as the MYC translocations of childhood
Burkitt lymphoma (BL) from China.
Methods: Fourty-three cases of childhood BL were retrospectively investigated in morphology, immunophenotype,
genotype, treatments and survival analysis.
Results: Clinically, there was a marked male predominance in sex distribution (M: F = 9.75:1); abdomen was the
most frequent extranodal sites of involvement (46.5 %), followed by jaws and facial bones (16.3 %). Two third of the
patients were in stageI ~ II. Morphologically, 69.76 % of the cases showed classical histologic features, while 30.24 %
of them showed greater nuclear pleomorphism in size and shape. Five cases (11.6 %) were positive for EBER1/2.
Thirty-one of the 40 cases (77.5 %) had the aberration of IGH/MYC translocation while 7 (17.5 %) had non-IGH/MYC
translocation. Thirty patients (69.7 %) received operation and/or chemotherapy while 13 patients (30.3 %) received
no treatment. Twenty-seven patients (62.8 %) died of the tumor, 16 alive, with the average survival time 4.9 and
48.7 months respectively. High IPI, advanced clinical stage, increased serum level of LDH and no chemotherapy
received as well as tumor size ≥10 cm were related to the lower survival rates of the tumor.
Conclusions: Several differences were showed in this group of BL, including a much higher ratio of male patients,
more cases in stageII, clinically inconsistent treatment and a very poor outcome.
Virtual slides: The virtual slide(s) for this article can be found here http://www.diagnosticpathology.diagnomx.eu/
vs/1552295877710135
Background
Burkitt lymphoma (BL) is defined by the updated WHO
classification (2008) as a B-cell lymphoma with an ex-
tremely short doubling time that often presents in extra-
nodal sites or as an acute leukemia [1]. BL is a highly
aggressive non-Hodgkin lymphoma (NHL) and character-
ized by C-MYC translocation. Three clinical variants of BL
are recognized, including endemic BL, sporadic BL and
immunodeficiency-associated BL. Sporadic BL is seen
throughout the world, mainly in children and adolescents.
Histologically, BL is characterized by diffuse infiltration of
monomorphic medium-sized neoplastic cells with baso-
philic cytoplasm and numerous mitotic figures; some
cases may have tumor cells with greater pleomorphism in
shape and nuclear size, which was designated as “atypical
BL” or “Burkitt like lymphoma” [2]. Although the inci-
dence of BL is low, accounting for only 1~ 2 % of all
lymphomas in western countries, it is one of the most
common types of malignant tumors in children and young
adults [1]. In the past decades, there were many reports of
sporadic BL, including cases from Asian countries and
areas [3,4], However, only a few cases of Chinese BL has
been reported in the English literature. In this study, 43
cases of BL of children and adolescents from southwest
China were retrospectively investigated for the clinical and
pathological features.
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Sixty cases of initially diagnosed Burkitt lymphoma of chil-
dren and adolescents (age ≤18 years) were received from
the Department of Pathology, West-China Hospital of
Sichuan University between 1990 and 2006. The specimens
fixed in 10 % neutral formalin (pH 7.2), were processed by
routine methods and embedded in paraffin. All cases were
reviewed by two expert heamatopathologists individually.
The criteria used to select the cases were as follows: (1)
cases diagnosed as Burkitt lymphoma (BL) with a typical
growth pattern and a high proliferation index (PI) as estab-
lished by Ki-67 staining (in general, >90 % nuclei positiv-
ity), occasionally with a some degree of pleomorphism in
nuclear size and shape, in accordance with WHO classifica-
tion (2008) [1]; (2) The neoplastic cells expressed B-cell dif-
ferentiation antigens (CD20), germinal center markers of
CD10 and /or BCL-6 but not BCL-2. 17 of 60 cases were
excluded because of insufficient materials for further stud-
ies. Thus, total 43 cases were included in current study.
The clinical history of each patient was reviewed for age at
diagnosis, gender, number and location of the tumor, sta-
ging, performance status, treatment regimens, complete
blood count (CBC), bone marrow aspiration/biopsy, serum
level of lactate dehydrogenase (LDH) and international
prognostic index (IPI). The staging was according to the
system proposed by Murphy and Hustu and modified by
Magrath [5]. The protocol of this study was approved by
the Institutional Review Board or ethical committee of
West China Hospital of Sichuan University.
Immunohistochemistry
Immunohistochemistry was performed on paraffin em-
bedded tissue sections using the Envision method (Dako,
Gene Ltd, China). Antigen retrieval techniques were ap-
plied as needed for each specific antibody. The following
antibodies were used: CD20, CD45RO, CD10, BCL-6
(Zymed, Zhongshan, China); CD3E, BCL-2, C-myc and
TdT and Ki-67 (Neumarkers, Maixin, China). DAB was
used as a substrate and the positive signal was dark
brown in color. The Ki-67 stain was assigned a percent-
age value that was calculated by positive nuclei staining
per 1000 tumor cell nuclei in each case.
In situ Hybridization for Epstein-Barr virus (EBV) encoded
RNA
In situ hybridization (ISH) was carried out with a
fluorescence-labeled oligonucleotide probe complementary
to two Epstein-Barr virus-encoded small RNAs, EBER-1
and EBER-2 (EBER1/2, Dako, Denmark, No.Y520001).
Rabbit anti-FITC antibody conjugated with alkaline phos-
phatase (Dako, Denmark) was used to combine with the
probe, whereas NBT/BCIP was used as a substrate. The
dark blue- purple hybridizing signal was located in cell
nucleus. The tumor was considered positive for EBV
encoded RNAs if more than 20 % of the tumor cells show-
ing reactivity.
Fluorescence In situ Hybridization for IGH/MYC and non-
IGH/MYC
Locus-specific interphase (LSI) fluorescence in situ
hybridization (FISH) was performed on paraffin-embedded
tissue sections. LSI MYC tri-color probe for the t(8;14)
(Vysis, Gene Ltd, China) were used to detect IGH/MYC;
LSI MYC dual color break apart rearrangement probe was
used to detect split ofMYC on chromosome 8 (Vysis, Gene
Ltd, China). Lymphomas with MYC breakpoint without fu-
sion of MYC to IGH locus were considered “other MYC
translocations”. Specifically, deparaffinized sections were
pretreated by pepsin digestion (30 min) in distilled water
and subsequently incubated in pepsin solution (100ug/ml,
10–30 min) at 370 C to increase DNA accessibility. Sections
were then fixed in 10 % neutral formalin for 5 min, dehy-
drated through increasing ethanol series and air-dried. 5ul
of probe mix was applied to the tissue section and covered
with a 10-mm cover slip. Both probe and target DNA were
simultaneously denatured at 800 C for 10 min and incubated
for up to 42~48 hours. Hybridization signals were analyzed
under the fluorescent microscope (BX51, OLYMPUS) with
appropriate filters. The images were captured using Applied
imaging system. A total of 200 nuclei were scored, and any
abnormal pattern which was present in excess of the cutoff
limits (>10 % of cells) was considered significant. RAJI cell
line was used as a positive control.
DNA extraction and polymerase chain reaction (PCR) for
the t(14;18)
Genomic DNA from paraffin-embedded tissue samples
was extracted by phenol-chloroform procedures. Success-
ful DNA extraction was confirmed by amplification of
110 bp fragment of β-globin. The primers of BIOMED-2
system were used for the t(14;18)(BCL2/IGH) analysis. The
experiment was according to the procedure of van Dongen
et al. [6]. The PCR products were electrophoresed in 10 %
nondenaturing polyacrylamide gel (acrylamide:biacryla-
mide ratio of 29:1), and silver staining was applied in
visualization of the results.
Follow up and statistical analysis
Clinical follow-up data were available for all of the forty-
three patients. Lymphoma-specific survival time was calcu-
lated by determining the time from the date of diagnosis to
the date of death or last follow-up, and was analyzed using
the Kaplan-Meier method. For comparison of the various
parameters, Fisher exact test was applied. A p value of 0.05
was considered statistically significant. All statistical analysis
was performed using SPSS software for Windows, version
13.0.




From 1990 to 2006, children and adolescents BL accounted
for 0.3 % (60/18960) of all malignant lymphomas, 0.8 %
(60/7429) of all non-Hodgin lymphoma and 7.1 % (60/850)
of all lymphomas of children and adolescents (age
≤18 years) in our hospital. The clinical features of the
patients were listed in Additional file 1: Table S1 and sum-
marized in Table 1. There were 39 boys and 4 girls with
male to female ratio 9.75:1. The Ages at diagnosis ranged
from 2 to 18 years with the mean and median age of 10.3
and 9 years, respectively. 36 patients (83.7 %) presented
with extranodal lesions while seven patients (16.3 %) dis-
played cervical or mandibular lymphadenopathy at presen-
tation. Twenty cases (20/43, 46.5 %) presented with
abdominal masses, followed by head and neck involvement
in 14 cases (14/43, 32.6 %). The mesentery with or without
greater omentum involvement represented the most fre-
quent extranodal site of involvement , accounting for
20.9 % of the cases, followed by ileocecum (8 cases,
18.6 %). Jaw and facial bone mass were presented in 7 cases
(16.3 %) (Figure 1). Constitutive B symptoms such as fever,
night sweat and weight loss were recorded in 17 patients
(39.5 %). Clinical presentation varied according to the ana-
tomic sites of involvement, e.g. in patients with abdominal
masses, abdominal pain, distension, diarrhea as well as in-
testinal obstruction were the main complains or signs; in
patients with jaw and cervical lymph node involvement,
rapidly enlarged masses were the common findings;
whereas in patients with nasopharyngeal or tonsilar
masses, the symptoms included nasal obstruction, epistaxis
and dysphagia. Except for one patient with Burkitt
Leukemia, no hepatosplenomegaly was recorded in the
other 42 patients. Comprehensive clinical examination data
were collected in 34 patients, with 24 patients presented
with low (low and low-intermediate) IPI scores and 10
patients with high (high and high-intermediate) IPI scores
respectively. Anemia, elevated white blood cell count and
thrombocythemia, and increased serum level of LDH were
found in 52.9 %, 35.3 %, 61.8 % and 67.9 % of the patients
respectively. According to the scheme proposed by
Murphy and Hustu and modified by Magrath, 28 patients
(66.7 %) were in stage I and II; nine (21.4 %) were in stage
III, including two of IIIA and one of IIIB, and the
remaining five (11.9 %) were in stage IV, including four
patients with central nervous system lesions and one
patients with bone marrow involvement. One patient suf-
fered from Burkitt leukemia, in whom hepatosplenome-
galy, increased lymphocyte count as well as bone marrow
involvement were presented at initial presentation.
Pathological findings
The size of the tumors ranged from 1.6x1.5x1.0 cm to
20.0x20.0x15.0 cm, in which 69.0 % of the cases were
larger than 5 cm in diameter. Various degrees of coagula-
tive necrosis and hemorrhage were presented in most of
the specimens. The morphologic features of the cases are
summarized in Table 2. Classical histologic features of
Burkitt lymphoma was presented in 30 of 43 cases












Jaws and facial bones 7 16.3
superficial lymph node 7 16.3
tonsils 3 7.0
nasopharynx 3 7.0
inner canthus 1 2.3
cerebellum 1 2.3
peripheral blood & bone marrow 1 2.3
B symptom 17 39.5
Bulky disease
<10 cm 35 81.4
≥10 cm 7 16.3
Lab findings (n = 34)
anemia 18 52.9
Increased WBC count 12 35.3
Increased PLT number 21 61.8
Increased serum level of LDH 23 67.6
Staging (n= 43, Jude and Murphy)
I / II 8/20 19.1/47.6
III / IV 9/6 21.4/11.9
IPI (n =34)
Low (0–2) 24 70.6
High (3–4) 10 29.4
Therapy (n= 30)
Surgery alone 10 33.3
Chemotherapy alone 11 36.7
Surgery and chemotherapy 9 30
Follow up (n=43, months)
Dead 27 62.8 (average 4.9 m)
Alive 16 37.2 (average 48.7 m)
Bi et al. Diagnostic Pathology 2012, 7:72 Page 3 of 11
http://www.diagnosticpathology.org/content/7/1/72
(69.8 %), which showed medium-sized neoplastic cells ar-
ranging in sheets with remarkably monomorphic consist-
ence in size and shape. The nuclei were round or oval
with finely clumped and dispersed chromatin and 2~4
basophilic medium sized, centrally situated nucleoli. The
cytoplasm was scarce to moderate and basophilic. Some
tumor cells presenting with dusty cytoplasm and invisible
nucleoli resembled lymphoblasts. In the remaining 13
cases (30.2 %), the neoplastic cells were less monomorphic
but showed greater nuclear pleomorphism in size and
shape, some of the tumor cells displayed more prominent
nucleoli resembling “immunoblast”. In addition, small
number of tumor giant cells was also seen in 3 cases.
“Starry Sky” growth pattern and “squared off” feature were
observed in 36 (83.7 %) and 31 (72.1 %) of the cases, re-
spectively. Abundant apoptosis was notable in 40 (93.0 %)
of the cases, and numerous mitotic figures were detected
in all of the tissue samples; Furthermore, more than 50 of
mitotic figures in 10 high power field (HPF) was detected
in 9 (20.9 %) of the cases, whereas 5 to 50 of mitotic
figures in 10 HPF was presented in 34 (79.1 %) of the cases
(Figure 2). No epithelioid granuloma was found in current
group of the cases, and “blood cell lake” was seen in 2
(4.7 %) cases.
For the seven cases with lymph node involvement, the
architecture of the node was completely effaced by diffuse
infiltration of neoplastic lymphoid cells. The other mor-
phologic features were similar as those described above.
Immunophenotype and EBV status
The results of immunohistochemistry and EBER-ISH
were summarized in Table 3. The neoplastic cells of all
cases expressed CD20 as well as CD10. In addition, 40
of 43 cases (93.0 %) were also positive for BCL-6 and 4
Table 2 Morphologic features (n =43)
Morphology NO. %
“Starry sky” pattern 36 83.7
Squared off feature 31 72.1
Coagulative necrosis 7 16.3
Greater nuclear pleomorphism 15 34.9
Tumor giant cells 3 7.0





Blood cell Lake 2 4.7
Figure 1 The macroscopic photograph of Burkitt lymphoma. (a) A 12-years boy presented with abdominal lesions. There was a huge mass
within the mesentery and multiple polyploid lesions were present in the cecum; (b) a 6-years boy had a jejunum mass, with thickening of
intestinal wall and hemorrhage; (c) an 8-years boy presented with a big facial bone mass.
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cases (9.3 %) were positive for CD45RO. No case showed
a positive reaction for BCL-2, TdT or CD3E. The neo-
plastic cells expressed C-MYC protein in 33 of the 43
cases. Ki-67 index was greater than 90 % in all of the
cases and greater than 95 % in 37 cases (Figure 3). Five
cases (11.6 %) were positive for EBER1/2 with the pro-
portion of positive cells ranging from 20 to 60 % (mean
40 %) (Figure 4a).
MYC gene translocation and BCL-2/IGH gene
rearrangement analysis
The FISH study was successfully performed in 40 cases,
the results are also summarized in Table 3. Of all 38
cases showing signal split with C-MYC break-apart FISH
probes, 31 (77.5 %) were positive for IGH/MYC fusion
FISH signals, indicating the t(8;14)(q24;q32) transloca-
tion; 7 (17.5 %) were negative for IGH/MYC, suggesting
IGL/MYC fusion or other rare translocation with MYC
(Figures 4b and 4c); in two cases the tumors were nega-
tive for both probes. The t(14;18) (BCL-2/IGH) t(14;18)
analysis by DNA amplification using PCR method was
performed in 39 cases and no BCL-2/IGH translocation
was identified.
Table 3 Results of IHC, EBER-ISH, PCR and FISH
Markers +/Number %










≤95 % 6/43 14.0
>95 % 37/43 86.0
EBER-ISH (n =43) 5/43 11.6
BCL-2/IGH by PCR (n =39) 0/39 0
FISH (n=40)
IGH/MYC 31/40 77.5
Other MYC translocation 7/40 17.5
* Polyclonal.
Figure 2 Histological feature of Burkitt lymphoma. (a) A nodal lesion showed the architecture of lymph node was totally effaced (H&Ex40);
(b) intestinal lesion showed tumor cells were diffusely infiltrated in the submucosa and also intruded into mucosa. (H&Ex40); (c) “starry sky” and
“square off” pattern were obviously seen. (H&Ex400); (d) a nodal lesion displayed a more pleomorphic feature with prominent nucleoli resembling
“immunoblast”. Abundant apoptosis and mitoses are present (H&Ex400).
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Treatment, Follow-up and Survival Analysis
Clinical treatment information were collected for all of the
43 patients. Nineteen patients (23.3 %) received surgical
resection, nine with combined chemotherapy subsequently.
Eleven patients (25.6 %) received chemotherapy alone,
whereas, unfortunately, the remaining 13 patients (30.4 %)
received no further treatment after the diagnosis was estab-
lished by biopsy. Among 20 patients who received chemo-
therapy, ten patients received CHOP-like regimen as initial
therapy, while the remaining ten patients received intensive
regimen including HYPER-CVAD or LMB. Among 20
patients who received chemotherapy with or without surgi-
cal resection, complete remissions (CR) and partial remis-
sions (PR) were achieved in 11 and 4 patients respectively,
whereas the remaining 5 patients failed to show any
response to chemotherapy.
Follow-up data was available for all of the 43 patients
(100 %). The mean follow-up time was 86.5 months, ran-
ging from 1 to 172 months. Twenty-seven of them (62.8 %)
died of the tumor with average survival of 4.9 months. At
the end of follow-up, 16 patients were alive with average
survival of 48.7 months. Patients without any treatment
were all died soon after diagnosis, whereas patients with ei-
ther surgical resection or chemotherapy treatment had bet-
ter outcomes (Figure 5a). For the 30 patients received
treatment, lymphoma specific overall survival (OS) were
analyzed in regard to various parameters, including IPI, age
(≤14 and> 14 years), staging (I/II and III/IV), elevation of
WBC and thrombocythemia, increased serum level of
LDH, with or without chemotherapy, size of the tumor
(<10 cm and ≥10 cm) and histomorphology (with or with-
out greater nuclear pleomorphism). As a result, high IPI,
advanced clinical stages (III and IV), without chemotherapy
received, bulky disease (≥10 cm) and increased serum level
of LDH were correlated to the poorer survival (Figures 5b
and 6). Although there was no prognostic difference be-
tween patients treated with CHOP-like regimen and inten-
sive regimen according to survival analysis, eight of ten
cases (80 %) with intensive regimen achieved CR after treat-
ment, whereas only three cases (30 %) in CHOP-like group
achieved CR.
Discussion
Herein, we reported clinicopathological features of 43
cases of pediatric BL from Southwest China. Pediatric BL
accounts for 7.1 % of all childhood lymphomas at our
hospital. It showed classical pathological features of BL
with typical morphology, immunohistochemical findings,
cytogenetic changes, and clinical features. However, our
study showed that a relatively lower incidence of BL in a
representative pediatric population in Southwest China,
Figure 3 Immunohistochemistry of Burkitt lymphoma. Tumor cells were positive for CD20 (a), CD10 (b), BCL-6 (c); nearly 100 % of tumor
cells were positive for Ki-67 (d) (x200).
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marked male predominance, and particularly poorer sur-
vival, partially due to insufficient therapy.
BL accounts for about 30~50 % of childhood lymph-
omas in the Western countries [1]. The reason for lower in-
cidence in our cohort is currently unknown. Cairo et al. [7]
reviewed 470 patients from USA, the male to female ratio
was 4:1 in that cohort. Chuang et al. [3] studied 17 pediatric
BL from Taiwan, the male to female ratio was 1.8:1;
whereas in current study, all patients but four were boys,
the ratio of male to female was 9.75:1. The gender ratio of
newborns in this part of China was about 1.2:1, and there
was no gender bias in patient selection. Our findings may
suggest BL were more prone to affect boy in this area. Fur-
ther larger scale of study is required to confirm this finding.
Majority of sporadic BL present with abdominal masses,
whereas jaw is rarely affected; majority of BL patients
(70 %) present at advanced stages [1].Whereas in our study,
close to one-thirds of patients presented with head and
neck lesions, together with the patients with superficial
lymph node involvement, resulting in a higher percentage
of cases in stage I/II in our cohort.
BL is a neoplasm of mature B-cell lineage, which was
thought to arise from germinal center B-cells [8]. Therefore,
the tumor cells often express germinal center associated
markers, such as CD10 and Bcl-6. Ki-67 index are always
nearly 100 % [9]. In current study, expression of CD10 and
BCL-6 were 100 % and 93 %, respectively, and Ki-67 index
was all beyond 90 %. No BCL-2 expression or BCL-2/IGH
gene rearrangement was detected in all examined cases.
The results are similar to that reported in the literatures.
The MYC translocation is a hallmark of Burkitt lymphoma.
The most common type of MYC translocation is the t(8;14)
(q24;q32), accounting for 80 % of BL; In the remaining
20 %, one of two variants is identified: t(2;8)(p12;q24) or t
(8;22)(q24;q11) [9]. In this study, MYC translocation was
found in 95 % of the cases, including 77.5 % of IGH/MYC
and 17.5 % of other translocations. Although MYC trans-
location detection by FISH was thought to be the “gold cri-
terion”, 9 %~14 % of the cases may lack a detectable MYC
translocation by FISH, the explanation for which is uncer-
tain [10-12].
The frequency of EBV infection in sporadic BL varied
largely according to geographical distributions, e.g. 0 %
to 8 % in Japan; 25 % of reported Taiwanese cases; 34 %
of Israel; 47 % of Argentina; 52.6 % of Brazil; 80 % of
India [13-16]. Some researchers suggested that general
Figure 4 (a) EBV-ISH showed positive for EBER1/2 (x400); (b) FISH study using tri-color dual fusion probe showed two fusion signals
indicating translocation between MYC and IGH (the aqua signal were CEP 8); (c) break-apart probe detected a break of MYC, which
indicating other MYC translocation in the absence of MYC/IGH translocation.
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conditions of health and social economic status may play
a role. In our study, 11.6 % of the cases were positive for
EBER1/2 by in situ hybridization, and it is lower than that
of average level (20 %~40 %) of EBV infection reported
[17]. Although EBV could be detected in almost all the en-
demic BL, to date, its significance in pathogenesis of the
sporadic BL is still controversy. In addition, Bellan [18]
studied the cell origin of BL by semi-nested PCR to amp-
lify the VDJ rearrangement of IG heavy chain (VH) genes
and sequencing analysis, the results suggested that EBV-
positive and EBV-negative BL may originate from two
distinct subsets of B-cells, pointing to a particular role for
Figure 6 Survival curves of 30 treated patients with regard to different parameters showed (a) Patients with normal level of LDH
(n= 11) had better prognoses over those with high level of LDH (n= 23)(P< 0.005); (b) patients with low stages (I & II, n = 20) had
better prognoses over those with advanced stages (III & IV, n = 10)(P< 0.001); (c) patients who received chemotherapy (n = 20) had
favorable outcomes than those who did not receive chemotherapy (n = 10)(P< 0.001); (d) patients with tumor size ≥10 cm (n = 5) has
worse outcomes than those with size< 10 cm (n = 25)(P< 0.005).
Figure 5 (a) The overall survival curve of 30 patients with treatment and 13 patients without treatment; (b) In treated patients, high
IPI (n = 9) had worse prognoses than those with low IPI (n = 16) (p< 0.001).
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Table 4 Review and comparison of the major clinical manifestations, treatment and outcome of BL
Authors Country/Region Number Age (years) M :F Abdomen (%) H & N (%) LN (%) CNS (%) Treatment Os or EFS (years)
Reiter A (1995) [23] Germany 152 0-17 3.6:1 / / / 4 BFM 86 EFS 79 %(1y)
EFS 79 %(2y)
Ertem U (1996) [24] Turkey 63 3-14 2:1 96.8 15.9 ≤3.2 % 7.9 Ziegler’s and intensive protocol* Os 60.0 %(1y)
Os 57.8 %(2y)
Cario MS (2003) [7] USA 470 0-21 3.7:1 / / / 12 COMP/LSA2L2 Os 70.0 (1y)
COMP/D-COMP EFS 60.0 %(1y)
CCG-552 Os 64.5 % (2y)
Orange/French** EFS 58.5 %(2y)
Boerma EG (2004) [25] Netherlands 66 0-15 4.5:1 >42 9 20 / / /
Hassan R (2008) [13] Brazil 54 2-14 2:1 72 2 11 4 / /
Chuang SS (2008) [3] Taiwan 17 0-16 1.8:1 41.2 41.2 17.6 11.8 CHOP(−like) Os 80 %(1y)
Modified BFM regimen Os 66.7 % (2y)
Mbulaiteye SM (2009) [26] USA 296 0-14 3.7:1 21 9 56 / /
The current study China 43 0-18 9.75:1 46.5 32.6 16.3 9.3 CHOP(−like) /Hyper-CVAD/ Os 39.5 %(1y)
LMB/ HD-MTX+Ara-c Os 39.5 %(2y)
* Eight drug intensive protocol, generated a favorable outcome than Ziegler’s protocol.














the germinal center reaction in the pathogenesis of the
tumor. Thorley’s research showed the similar results as
well [19].
Although BL was less common in adults and the present
study mainly focused on children and adolescents, pediatric
and adult sporadic BLs shared similar phenotypic and
genotypic features [8]. A study based on gene expression
profiling by Klapper et al. [20] showed the same results,
that no differences were detectable between pediatric and
adult molecular BL with regard to gene expression and
chromosomal imbalances.
The following morphologic features, such as sheets of
monomorphic and medium-sized neoplastic cells, “starry
sky” growth pattern, numerous mitotic figures as well as
apoptotic bodies favor the diagnosis of BL. Molecular pro-
filing studies also showed that the histomorphological diag-
nosis of classical Burkitt lymphoma is quite robust [11,21].
Furthermore, in combination with immunohistochemistry,
MYC translocation by FISH, diagnosis of BL is usually easy
to make in most instances. However, the neoplastic cells of
BL may also display a variety degree of pleomorphism in
nuclear size and shape, which was described as Burkitt like
lymphoma (BLL) and categorized as a variant of BL in
WHO Classifications of 2001 [2]. The major problem is to
distinguish BL with greater pleomorphism from DLBCL.
Gene-expression profiling has confirmed that BL is a
homogenous molecular phenotype clearly distinct from
other B-NHL including DLBCL [8,11,21,22]. Nevertheless,
it is currently impractical for us to use gene-expression
profiling analysis in routine diagnosis. Some tumors with
histomorphological and immunohistochemical features
intermediate between BL and DLBCL, so called “gray zone
lymphoma” are present and further studies are wanted for
understanding the pathogenesis of this group of tumors as
well as their effective therapy.
Despite the fact that BL is a highly aggressive lymphoma
with a double time of 25.6 h, it is potentially curable. Inten-
sive combination chemotherapy regimens result in cure
rates up to 90 % in patients with low stage disease and 60
~80 % in patients with advanced stage disease [1]. We
reviewed the major clinical manifestations, treatment and
outcome of BL reported in English literatures in the last
decade (Table 4) [3,7,13,23-26]. The patients in current
study had a relatively poor prognosis with both one and
two years overall survival rates at only 39.5 %. The possible
reasons may include, but not limited to: (1) less than 50 %
of the patients received chemotherapy, and about one-third
of patients gave up the further treatment; (2) the chemo-
therapy regimens used were inappropriate or inadequate.
CHOP-like regimen, the most commonly selected therapy
for DLBCL was not suitable for BL [27,28]. Short and in-
tensive therapy, including methotrexate and Ara-C is
recommended and is associated with a significant improve-
ment in patients with BL, even for those with advanced
stages [29-31]. In our study, although there was no survival
difference between patients treated with CHIOP-like regi-
men and intensive therapy, it was striking that intensive
therapy could result in CR in most patients, indicating its
advantage in the initial therapy. In addition, high IPI,
advanced clinical stage (III/IV), bulky disease, and increased
serum level of LDH were also related to the lower survival,
which suggest BL is a curable disease in children and ado-
lescents, however, early diagnosis and therapy is crucial for
improving the clinical outcome.
In conclusion, we described 43 cases of childhood BL.
Compared with that reported in the literature, some differ-
ences were presented in our cohort, including the higher
ratio of male patients and higher percentage of patients
presented with lower stages, clinically insufficient treatment
and management as well as a very poor outcome of the
tumor. Because BL was not common in mainland China, It
is necessary for us to ameliorate the management and
treatment of the tumor to improve the prognosis in the
near future.
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Additional file 1: Table S1. Clinical manifestations and follow-up data.
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